Interaction between TGFβ signaling proteins and C/EBP controls basal and tat-mediated transcription of HIV-1 LTR in astrocytes

被引:33
作者
Coyle-Rink, J
Sweet, TM
Abraham, S
Sawaya, BE
Batuman, O
Khalili, K
Amini, S
机构
[1] Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA
[2] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1006/viro.2002.1439
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Signal transduction pathways induced by cytokines can modulate the level of HIV-1 gene transcription and replication in a variety of cells including those from the central nervous system. Here, we investigated the effect of TGFbeta-1 signaling the factors, including Smads, on transcription of the viral LTR in human astrocytic cells. Ectopic expression of Smad-3 increased activity of the viral promoter, while its partner protein, Smad-4, caused a slight decrease in viral gene transcription. Further, Smad-4 was able to suppress transcriptional activation of the LTR by Smad-3 as well as by C/EBPbeta, another activator of LTR transcription in these cells. Results from promoter deletion experiments identified the C/EBP-binding site, which is positioned between nucleotides -114 and -102 as one of the targets for Smad-mediated regulation of the LTR. Band-shift studies showed inhibition of C/EBP binding to its target DNA in protein extract from cells overexpressing Smad-3 and Smad-4. Results from GST pull-down assay and combined immunoprecipitation/Western blot of protein extracts from human astrocytes verified the association of Smad-3 and Smad-4 with C/EBPbeta, suggesting that interaction of C/EBPbeta with Smad-3 and Smad-4 may have a negative impact upon C/EBPbeta-mediated activation of the LTR. Interestingly, Smad-4 showed no inhibitory effect on viral gene transcription in cells expressing Tat protein. However, in the presence of Smad-3, expression of Smad-4 exerted a negative effect on Tat-mediated activation of the LTR promoter. These observations pointed to the functional interplay between viral and cellular proteins in modulating LTR transcription. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:240 / 247
页数:8
相关论文
共 41 条
[1]  
ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689
[2]   STIMULATION OF HIV TYPE-1 GENE-EXPRESSION AND INDUCTION OF NF-KAPPA-B (P50/P65)-BINDING ACTIVITY IN TUMOR NECROSIS FACTOR-ALPHA-TREATED HUMAN FETAL GLIAL-CELLS [J].
ATWOOD, WJ ;
TORNATORE, CS ;
TRAUB, R ;
CONANT, K ;
DREW, PD ;
MAJOR, EO .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (10) :1207-1211
[3]   TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1 LEAD TO PHOSPHORYLATION AND LOSS OF I-KAPPA-B-ALPHA - A MECHANISM FOR NF-KAPPA-B ACTIVATION [J].
BEG, AA ;
FINCO, TS ;
NANTERMET, PV ;
BALDWIN, AS .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (06) :3301-3310
[4]   Interleukin-1 receptor antagonist as a treatment of HIV infection [J].
Corley, PA .
MEDICAL HYPOTHESES, 2000, 54 (04) :513-518
[5]  
CUPP C, 1993, ONCOGENE, V8, P2231
[6]   HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) INFECTION OF THE CENTRAL NERVOUS-SYSTEM - AN EVALUATION OF CYTOKINES IN CEREBROSPINAL-FLUID [J].
GALLO, P ;
FREI, K ;
RORDORF, C ;
LAZDINS, J ;
TAVOLATO, B ;
FONTANA, A .
JOURNAL OF NEUROIMMUNOLOGY, 1989, 23 (02) :109-116
[7]   TGF-beta signalling from cell membrane to nucleus through SMAD proteins [J].
Heldin, CH ;
Miyazono, K ;
tenDijke, P .
NATURE, 1997, 390 (6659) :465-471
[8]   C/EBP PROTEINS ACTIVATE TRANSCRIPTION FROM THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT IN MACROPHAGES MONOCYTES [J].
HENDERSON, AJ ;
ZOU, X ;
CALAME, KL .
JOURNAL OF VIROLOGY, 1995, 69 (09) :5337-5344
[9]   C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines [J].
Henderson, AJ ;
Connor, RI ;
Calame, KL .
IMMUNITY, 1996, 5 (01) :91-101
[10]   Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G [J].
Jeeninga, RE ;
Hoogenkamp, M ;
Armand-Ugon, M ;
de Baar, M ;
Verhoef, K ;
Berkhout, B .
JOURNAL OF VIROLOGY, 2000, 74 (08) :3740-3751